25 XP   0   0   10

Mayne Pharma Group Ltd
Buy, Hold or Sell?

Let's analyse Mayne Pharma Group Ltd together

PenkeI guess you are interested in Mayne Pharma Group Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Mayne Pharma Group Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Mayne Pharma Group Ltd

I send you an email if I find something interesting about Mayne Pharma Group Ltd.

Quick analysis of Mayne Pharma Group Ltd (30 sec.)










What can you expect buying and holding a share of Mayne Pharma Group Ltd? (30 sec.)

How much money do you get?

How much money do you get?
A$1.42
When do you have the money?
1 year
How often do you get paid?
70.0%

What is your share worth?

Current worth
A$7.46
Expected worth in 1 year
A$11.09
How sure are you?
60.0%

+ What do you gain per year?

Total Gains per Share
A$5.76
Return On Investment
107.9%

For what price can you sell your share?

Current Price per Share
A$5.34
Expected price per share
A$5 - A$7.4
How sure are you?
50%

1. Valuation of Mayne Pharma Group Ltd (5 min.)




Live pricePrice per Share (EOD)

A$5.34

Intrinsic Value Per Share

A$-41.66 - A$-4.80

Total Value Per Share

A$-34.20 - A$2.66

2. Growth of Mayne Pharma Group Ltd (5 min.)




Is Mayne Pharma Group Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$423.1m$371.6m$51.5m12.2%

How much money is Mayne Pharma Group Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$211m-$187.6m-$23.4m-11.1%
Net Profit Margin-172.4%-179.0%--

How much money comes from the company's main activities?

3. Financial Health of Mayne Pharma Group Ltd (5 min.)




What can you expect buying and holding a share of Mayne Pharma Group Ltd? (5 min.)

Welcome investor! Mayne Pharma Group Ltd's management wants to use your money to grow the business. In return you get a share of Mayne Pharma Group Ltd.

What can you expect buying and holding a share of Mayne Pharma Group Ltd?

First you should know what it really means to hold a share of Mayne Pharma Group Ltd. And how you can make/lose money.

Speculation

The Price per Share of Mayne Pharma Group Ltd is A$5.34. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Mayne Pharma Group Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Mayne Pharma Group Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$7.46. Based on the TTM, the Book Value Change Per Share is A$0.91 per quarter. Based on the YOY, the Book Value Change Per Share is A$-2.52 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.53 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Mayne Pharma Group Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps0.9217.2%0.9217.2%-2.06-38.7%-1.14-21.3%-0.55-10.4%
Usd Book Value Change Per Share0.6111.3%0.6111.3%-1.68-31.5%-0.94-17.6%0.407.5%
Usd Dividend Per Share0.366.7%0.366.7%0.366.7%0.285.3%0.8716.2%
Usd Total Gains Per Share0.9618.0%0.9618.0%-1.33-24.8%-0.66-12.3%1.2723.8%
Usd Price Per Share2.94-2.94-0.17-0.78-0.77-
Price to Earnings Ratio3.19-3.19--0.08-0.49-2.15-
Price-to-Total Gains Ratio3.05-3.05--0.13-0.61-0.70-
Price to Book Ratio0.59-0.59-0.04-0.15-0.20-
Price-to-Total Gains Ratio3.05-3.05--0.13-0.61-0.70-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.562314
Number of shares280
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.360.28
Usd Book Value Change Per Share0.61-0.94
Usd Total Gains Per Share0.96-0.66
Gains per Quarter (280 shares)269.03-184.27
Gains per Year (280 shares)1,076.12-737.07
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
13986781066318-1055-747
279613572142636-2111-1484
3119320353218955-3166-2221
41591271342941273-4221-2958
51989339253701591-5276-3695
62387407064461909-6332-4432
72784474875222228-7387-5169
83182542785982546-8442-5906
93580610596742864-9498-6643
1039786783107503182-10553-7380

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%1.02.00.033.3%1.04.00.020.0%5.05.00.050.0%8.09.01.044.4%
Book Value Change Per Share1.00.00.0100.0%1.02.00.033.3%2.03.00.040.0%6.04.00.060.0%11.07.00.061.1%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%4.00.01.080.0%7.00.03.070.0%10.00.08.055.6%
Total Gains per Share1.00.00.0100.0%1.02.00.033.3%2.03.00.040.0%6.04.00.060.0%12.06.00.066.7%

Fundamentals of Mayne Pharma Group Ltd

About Mayne Pharma Group Ltd

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: International Branded Products, and Portfolio Product Division. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

Fundamental data was last updated by Penke on 2024-05-18 08:46:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is cheap.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Mayne Pharma Group Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Mayne Pharma Group Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers - General industry mean.
  • A Net Profit Margin of -172.4% means that $-1.72 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Mayne Pharma Group Ltd:

  • The MRQ is -172.4%. The company is making a huge loss. -2
  • The TTM is -172.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-172.4%TTM-172.4%0.0%
TTM-172.4%YOY-179.0%+6.6%
TTM-172.4%5Y-95.4%-77.0%
5Y-95.4%10Y-45.2%-50.2%
1.1.2. Return on Assets

Shows how efficient Mayne Pharma Group Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers - General industry mean.
  • -25.4% Return on Assets means that Mayne Pharma Group Ltd generated $-0.25 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Mayne Pharma Group Ltd:

  • The MRQ is -25.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -25.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-25.4%TTM-25.4%0.0%
TTM-25.4%YOY-21.8%-3.5%
TTM-25.4%5Y-16.7%-8.6%
5Y-16.7%10Y-7.4%-9.3%
1.1.3. Return on Equity

Shows how efficient Mayne Pharma Group Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers - General industry mean.
  • -49.9% Return on Equity means Mayne Pharma Group Ltd generated $-0.50 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Mayne Pharma Group Ltd:

  • The MRQ is -49.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -49.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-49.9%TTM-49.9%0.0%
TTM-49.9%YOY-49.8%-0.1%
TTM-49.9%5Y-32.7%-17.2%
5Y-32.7%10Y-14.1%-18.5%

1.2. Operating Efficiency of Mayne Pharma Group Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Mayne Pharma Group Ltd is operating .

  • Measures how much profit Mayne Pharma Group Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers - General industry mean.
  • An Operating Margin of -101.6% means the company generated $-1.02  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Mayne Pharma Group Ltd:

  • The MRQ is -101.6%. The company is operating very inefficient. -2
  • The TTM is -101.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-101.6%TTM-101.6%0.0%
TTM-101.6%YOY-77.6%-24.0%
TTM-101.6%5Y-35.2%-66.4%
5Y-35.2%10Y-9.2%-26.0%
1.2.2. Operating Ratio

Measures how efficient Mayne Pharma Group Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • An Operation Ratio of 2.02 means that the operating costs are $2.02 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Mayne Pharma Group Ltd:

  • The MRQ is 2.016. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.016. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.016TTM2.0160.000
TTM2.016YOY1.776+0.240
TTM2.0165Y1.352+0.664
5Y1.35210Y1.104+0.248

1.3. Liquidity of Mayne Pharma Group Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Mayne Pharma Group Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A Current Ratio of 1.78 means the company has $1.78 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Mayne Pharma Group Ltd:

  • The MRQ is 1.780. The company is able to pay all its short-term debts. +1
  • The TTM is 1.780. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.780TTM1.7800.000
TTM1.780YOY0.838+0.942
TTM1.7805Y1.793-0.012
5Y1.79310Y1.865-0.072
1.3.2. Quick Ratio

Measures if Mayne Pharma Group Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers - General industry mean.
  • A Quick Ratio of 1.74 means the company can pay off $1.74 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Mayne Pharma Group Ltd:

  • The MRQ is 1.745. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.745. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.745TTM1.7450.000
TTM1.745YOY0.807+0.938
TTM1.7455Y1.395+0.350
5Y1.39510Y1.355+0.040

1.4. Solvency of Mayne Pharma Group Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Mayne Pharma Group Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Mayne Pharma Group Ltd to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.49 means that Mayne Pharma Group Ltd assets are financed with 49.1% credit (debt) and the remaining percentage (100% - 49.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Mayne Pharma Group Ltd:

  • The MRQ is 0.491. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.491. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.491TTM0.4910.000
TTM0.491YOY0.567-0.076
TTM0.4915Y0.468+0.023
5Y0.46810Y0.453+0.015
1.4.2. Debt to Equity Ratio

Measures if Mayne Pharma Group Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 96.6% means that company has $0.97 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Mayne Pharma Group Ltd:

  • The MRQ is 0.966. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.966. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.966TTM0.9660.000
TTM0.966YOY1.294-0.328
TTM0.9665Y0.906+0.060
5Y0.90610Y1.006-0.100

2. Market Valuation of Mayne Pharma Group Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Mayne Pharma Group Ltd generates.

  • Above 15 is considered overpriced but always compare Mayne Pharma Group Ltd to the Drug Manufacturers - General industry mean.
  • A PE ratio of 3.19 means the investor is paying $3.19 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Mayne Pharma Group Ltd:

  • The EOD is 3.875. Based on the earnings, the company is cheap. +2
  • The MRQ is 3.193. Based on the earnings, the company is cheap. +2
  • The TTM is 3.193. Based on the earnings, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD3.875MRQ3.193+0.682
MRQ3.193TTM3.1930.000
TTM3.193YOY-0.081+3.273
TTM3.1935Y0.495+2.698
5Y0.49510Y2.150-1.655
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Mayne Pharma Group Ltd:

  • The EOD is -1.732. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.427. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.427. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.732MRQ-1.427-0.305
MRQ-1.427TTM-1.4270.000
TTM-1.427YOY-0.747-0.680
TTM-1.4275Y0.027-1.454
5Y0.02710Y1.513-1.486
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Mayne Pharma Group Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 0.59 means the investor is paying $0.59 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Mayne Pharma Group Ltd:

  • The EOD is 0.716. Based on the equity, the company is cheap. +2
  • The MRQ is 0.590. Based on the equity, the company is cheap. +2
  • The TTM is 0.590. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.716MRQ0.590+0.126
MRQ0.590TTM0.5900.000
TTM0.590YOY0.038+0.552
TTM0.5905Y0.148+0.443
5Y0.14810Y0.201-0.054
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Mayne Pharma Group Ltd.

3.1. Funds holding Mayne Pharma Group Ltd

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Mayne Pharma Group Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.9080.9080%-2.521+378%-1.412+256%0.604+50%
Book Value Per Share--7.4577.4570%6.549+14%9.449-21%8.727-15%
Current Ratio--1.7801.7800%0.838+112%1.793-1%1.865-5%
Debt To Asset Ratio--0.4910.4910%0.567-13%0.468+5%0.453+8%
Debt To Equity Ratio--0.9660.9660%1.294-25%0.906+7%1.006-4%
Dividend Per Share--0.5320.5320%0.5320%0.426+25%1.299-59%
Eps--1.3781.3780%-3.095+325%-1.708+224%-0.829+160%
Free Cash Flow Per Share---3.083-3.0830%-0.335-89%-0.285-91%-0.129-96%
Free Cash Flow To Equity Per Share---8.160-8.1600%0.100-8227%-1.307-84%0.892-1015%
Gross Profit Margin--1.3981.3980%1.372+2%1.423-2%0.858+63%
Intrinsic Value_10Y_max---4.801--------
Intrinsic Value_10Y_min---41.657--------
Intrinsic Value_1Y_max---0.205--------
Intrinsic Value_1Y_min---1.858--------
Intrinsic Value_3Y_max---0.827--------
Intrinsic Value_3Y_min---7.623--------
Intrinsic Value_5Y_max---1.702--------
Intrinsic Value_5Y_min---15.577--------
Market Cap454296783.360+18%374326937.600374326937.6000%21268576.000+1660%99792158.592+275%98345895.424+281%
Net Profit Margin---1.724-1.7240%-1.790+4%-0.954-45%-0.452-74%
Operating Margin---1.016-1.0160%-0.776-24%-0.352-65%-0.092-91%
Operating Ratio--2.0162.0160%1.776+14%1.352+49%1.104+83%
Pb Ratio0.716+18%0.5900.5900%0.038+1446%0.148+300%0.201+193%
Pe Ratio3.875+18%3.1933.1930%-0.081+103%0.495+546%2.150+49%
Price Per Share5.340+18%4.4004.4000%0.250+1660%1.173+275%1.156+281%
Price To Free Cash Flow Ratio-1.732-21%-1.427-1.4270%-0.747-48%0.027-5401%1.513-194%
Price To Total Gains Ratio3.708+18%3.0553.0550%-0.126+104%0.612+400%0.700+336%
Quick Ratio--1.7451.7450%0.807+116%1.395+25%1.355+29%
Return On Assets---0.254-0.2540%-0.218-14%-0.167-34%-0.074-71%
Return On Equity---0.499-0.4990%-0.4980%-0.327-34%-0.141-72%
Total Gains Per Share--1.4401.4400%-1.988+238%-0.986+168%1.902-24%
Usd Book Value--423181556.000423181556.0000%371654752.000+14%536274618.740-21%495303404.750-15%
Usd Book Value Change Per Share--0.6060.6060%-1.682+378%-0.942+256%0.403+50%
Usd Book Value Per Share--4.9744.9740%4.369+14%6.304-21%5.822-15%
Usd Dividend Per Share--0.3550.3550%0.3550%0.284+25%0.867-59%
Usd Eps--0.9190.9190%-2.065+325%-1.139+224%-0.553+160%
Usd Free Cash Flow---174978328.700-174978328.7000%-18993003.433-89%-16178108.807-91%-7304744.933-96%
Usd Free Cash Flow Per Share---2.057-2.0570%-0.223-89%-0.190-91%-0.086-96%
Usd Free Cash Flow To Equity Per Share---5.443-5.4430%0.067-8227%-0.872-84%0.595-1015%
Usd Market Cap303061384.179+18%249713500.073249713500.0730%14188267.050+1660%66571348.997+275%65606546.837+281%
Usd Price Per Share3.562+18%2.9352.9350%0.167+1660%0.783+275%0.771+281%
Usd Profit---211083114.900-211083114.9000%-187645890.600-11%-157184770.400-26%-77192342.430-63%
Usd Revenue--122470220.600122470220.6000%104832763.700+17%229976987.807-47%225239643.867-46%
Usd Total Gains Per Share--0.9610.9610%-1.327+238%-0.658+168%1.269-24%
 EOD+5 -3MRQTTM+0 -0YOY+21 -135Y+14 -2210Y+12 -24

4.2. Fundamental Score

Let's check the fundamental score of Mayne Pharma Group Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-153.875
Price to Book Ratio (EOD)Between0-10.716
Net Profit Margin (MRQ)Greater than0-1.724
Operating Margin (MRQ)Greater than0-1.016
Quick Ratio (MRQ)Greater than11.745
Current Ratio (MRQ)Greater than11.780
Debt to Asset Ratio (MRQ)Less than10.491
Debt to Equity Ratio (MRQ)Less than10.966
Return on Equity (MRQ)Greater than0.15-0.499
Return on Assets (MRQ)Greater than0.05-0.254
Total6/10 (60.0%)

4.3. Technical Score

Let's check the technical score of Mayne Pharma Group Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5025.917
Ma 20Greater thanMa 506.704
Ma 50Greater thanMa 1006.876
Ma 100Greater thanMa 2006.301
OpenGreater thanClose5.430
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-06-302020-06-302021-06-302022-06-302023-06-30
Net Debt  280,378-20,116260,262-11,423248,83968,155316,994-362,105-45,111
Other Stockholders Equity  125,01124,592149,603-60,72088,88359,759148,642-612,564-463,922
Net Income Applicable to Common Shares  -279,203186,414-92,789-115,634-208,423-54,920-263,343380,592117,249



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets1,247,354
Total Liabilities612,994
Total Stockholder Equity634,360
 As reported
Total Liabilities 612,994
Total Stockholder Equity+ 634,360
Total Assets = 1,247,354

Assets

Total Assets1,247,354
Total Current Assets553,629
Long-term Assets693,725
Total Current Assets
Cash And Cash Equivalents 92,616
Short-term Investments 127,526
Net Receivables 194,887
Inventory 82,700
Other Current Assets 28,173
Total Current Assets  (as reported)553,629
Total Current Assets  (calculated)525,902
+/- 27,727
Long-term Assets
Property Plant Equipment 51,482
Intangible Assets 617,264
Other Assets 24,979
Long-term Assets  (as reported)693,725
Long-term Assets  (calculated)693,725
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities310,959
Long-term Liabilities302,035
Total Stockholder Equity634,360
Total Current Liabilities
Short-term Debt 14,427
Short Long Term Debt 10,810
Accounts payable 32,027
Other Current Liabilities 22,854
Total Current Liabilities  (as reported)310,959
Total Current Liabilities  (calculated)80,118
+/- 230,841
Long-term Liabilities
Long term Debt Total 33,078
Other Liabilities 268,957
Deferred Long Term Liability 2,039
Long-term Liabilities  (as reported)302,035
Long-term Liabilities  (calculated)304,074
+/- 2,039
Total Stockholder Equity
Common Stock1,233,692
Retained Earnings -769,770
Accumulated Other Comprehensive Income 170,438
Total Stockholder Equity (as reported)634,360
Total Stockholder Equity (calculated)634,360
+/-0
Other
Capital Stock1,233,692
Cash and Short Term Investments 220,142
Common Stock Shares Outstanding 83,155
Current Deferred Revenue241,651
Liabilities and Stockholders Equity 1,247,354
Net Debt -45,111
Net Invested Capital 673,650
Net Tangible Assets 19,135
Net Working Capital 242,670
Property Plant and Equipment Gross 99,803
Short Long Term Debt Total 47,505



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-30
> Total Assets 
29
15,510
11,693
8,036
71,149
53,677
53,933
233,391
265,820
528,946
1,557,381
1,914,920
1,830,507
1,636,333
1,825,180
1,463,184
1,287,926
1,247,354
1,247,3541,287,9261,463,1841,825,1801,636,3331,830,5071,914,9201,557,381528,946265,820233,39153,93353,67771,1498,03611,69315,51029
   > Total Current Assets 
0
15,453
11,648
8,013
32,529
18,838
23,255
61,909
65,895
156,820
1,108,650
429,003
480,767
471,946
490,947
416,528
511,618
553,629
553,629511,618416,528490,947471,946480,767429,0031,108,650156,82065,89561,90923,25518,83832,5298,01311,64815,4530
       Cash And Cash Equivalents 
29
15,303
11,531
7,936
19,709
5,807
11,596
18,938
14,813
59,201
47,481
63,027
87,312
89,004
137,785
97,980
96,672
92,616
92,61696,67297,980137,78589,00487,31263,02747,48159,20114,81318,93811,5965,80719,7097,93611,53115,30329
       Short-term Investments 
0
0
0
0
0
0
0
1,825
1,172
2,229
3,458
6,208
6,747
563
0
0
127,526
127,526
127,526127,526005636,7476,2083,4582,2291,1721,8250000000
       Net Receivables 
0
80
47
39
5,999
5,697
3,821
24,622
29,805
64,657
123,716
232,716
252,715
256,580
195,908
183,283
268,241
194,887
194,887268,241183,283195,908256,580252,715232,716123,71664,65729,80524,6223,8215,6975,9993947800
       Other Current Assets 
0
70
70
37
321
911
594
2,931
2,869
8,289
895,052
20,658
51,837
26,014
63,257
32,755
37,797
28,173
28,17337,79732,75563,25726,01451,83720,658895,0528,2892,8692,9315949113213770700
   > Long-term Assets 
0
57
45
23
38,621
34,839
30,678
171,482
199,925
372,126
448,731
1,485,917
1,349,740
1,164,387
1,334,233
1,046,656
776,308
693,725
693,725776,3081,046,6561,334,2331,164,3871,349,7401,485,917448,731372,126199,925171,48230,67834,83938,6212345570
       Property Plant Equipment 
0
57
45
23
21,047
21,457
22,224
55,036
53,409
59,597
84,449
189,272
230,051
236,034
238,244
221,595
225,855
51,482
51,482225,855221,595238,244236,034230,051189,27284,44959,59753,40955,03622,22421,45721,0472345570
       Goodwill 
0
0
0
0
391
391
391
47,197
47,476
58,436
60,115
58,217
20,616
21,725
22,174
20,346
22,127
0
022,12720,34622,17421,72520,61658,21760,11558,43647,47647,1973913913910000
       Long Term Investments 
0
0
0
0
0
0
0
0
4,076
0
0
0
0
0
0
0
0
0
0000000004,07600000000
       Intangible Assets 
0
0
0
0
13,835
7,792
3,803
68,273
93,639
244,524
272,368
1,177,224
1,033,910
775,907
940,117
615,808
405,387
617,264
617,264405,387615,808940,117775,9071,033,9101,177,224272,368244,52493,63968,2733,8037,79213,8350000
       Other Assets 
0
0
0
0
3,347
5,199
4,260
18,981
34,763
9,569
31,799
152,815
167,389
183,499
174,398
-302,376
-606,224
24,979
24,979-606,224-302,376174,398183,499167,389152,81531,7999,56934,76318,9814,2605,1993,3470000
> Total Liabilities 
7
996
255
332
45,600
29,503
23,333
112,502
106,546
206,744
1,181,160
602,496
595,350
622,258
782,867
691,605
730,806
612,994
612,994730,806691,605782,867622,258595,350602,4961,181,160206,744106,546112,50223,33329,50345,6003322559967
   > Total Current Liabilities 
7
991
253
318
23,167
14,939
12,304
42,111
30,379
95,078
1,055,924
199,895
179,897
211,329
219,253
222,527
610,421
310,959
310,959610,421222,527219,253211,329179,897199,8951,055,92495,07830,37942,11112,30414,93923,1673182539917
       Short-term Debt 
0
3
3
2
7,587
2,339
0
7,471
2,374
2,229
503
13,124
58
50,881
44,836
54,043
407,993
14,427
14,427407,99354,04344,83650,8815813,1245032,2292,3747,47102,3397,5872330
       Short Long Term Debt 
0
0
0
0
0
0
0
0
48,030
61,756
76,834
13,011
374,190
50,861
44,836
51,158
405,367
10,810
10,810405,36751,15844,83650,861374,19013,01176,83461,75648,03000000000
       Accounts payable 
7
166
135
119
2,227
2,142
2,893
6,832
7,131
51,572
135,508
66,593
63,888
50,443
29,842
42,363
63,571
32,027
32,02763,57142,36329,84250,44363,88866,593135,50851,5727,1316,8322,8932,1422,2271191351667
       Other Current Liabilities 
0
821
115
197
13,353
10,458
9,411
27,808
20,874
43,506
919,913
120,178
115,951
110,005
144,575
126,121
138,857
22,854
22,854138,857126,121144,575110,005115,951120,178919,91343,50620,87427,8089,41110,45813,3531971158210
   > Long-term Liabilities 
0
6
2
14
22,433
14,564
11,029
70,391
76,167
111,666
125,236
402,601
415,453
410,929
563,614
469,078
120,385
302,035
302,035120,385469,078563,614410,929415,453402,601125,236111,66676,16770,39111,02914,56422,43314260
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
62,754
76,331
327,122
374,132
318,501
353,211
292,776
5,673
33,078
33,0785,673292,776353,211318,501374,132327,12276,33162,754000000000
       Other Liabilities 
0
6
2
14
15,856
10,086
7,299
10,594
8,726
49,910
48,905
75,479
40,494
92,430
210,403
176,302
114,712
268,957
268,957114,712176,302210,40392,43040,49475,47948,90549,9108,72610,5947,29910,08615,85614260
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
33,438
51,562
72,048
91,611
102,225
53,373
40,700
-491,283
-729,163
2,039
2,039-729,163-491,28340,70053,373102,22591,61172,04851,56233,43800000000
> Total Stockholder Equity
21
14,514
11,438
7,704
25,550
24,174
30,600
120,889
159,274
310,870
363,749
1,303,838
1,226,464
1,007,766
1,037,547
768,357
564,773
634,360
634,360564,773768,3571,037,5471,007,7661,226,4641,303,838363,749310,870159,274120,88930,60024,17425,5507,70411,43814,51421
   Common Stock
30
15,908
15,869
15,869
29,649
31,870
32,016
118,302
137,498
255,834
263,161
1,130,404
1,131,761
1,140,008
1,238,584
1,238,537
1,238,537
1,233,692
1,233,6921,238,5371,238,5371,238,5841,140,0081,131,7611,130,404263,161255,834137,498118,30232,01631,87029,64915,86915,86915,90830
   Retained Earnings Total Equity000000000000000000
   Accumulated Other Comprehensive Income 
0
439
875
902
1,714
960
1,087
7,461
5,360
30,861
39,058
23,337
71,178
125,099
149,603
88,883
148,642
170,438
170,438148,64288,883149,603125,09971,17823,33739,05830,8615,3607,4611,0879601,7149028754390
   Capital Surplus 000000000000000000
   Treasury Stock000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
5,360
27,631
29,928
23,337
71,178
125,011
149,603
88,883
148,642
-463,922
-463,922148,64288,883149,603125,01171,17823,33729,92827,6315,36000000000



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.